PMC:7105881 / 26079-26294 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"769","span":{"begin":34,"end":42},"obj":"Species"}],"attributes":[{"id":"A769","pred":"tao:has_database_id","subj":"769","obj":"Tax:694009"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Numerous subunit vaccines against SARS-CoV have been developed since the outbreak of SARS, the majority of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T114","span":{"begin":123,"end":130},"obj":"Body_part"}],"attributes":[{"id":"A114","pred":"fma_id","subj":"T114","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Numerous subunit vaccines against SARS-CoV have been developed since the outbreak of SARS, the majority of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T112","span":{"begin":34,"end":42},"obj":"Disease"},{"id":"T113","span":{"begin":85,"end":89},"obj":"Disease"}],"attributes":[{"id":"A112","pred":"mondo_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A113","pred":"mondo_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Numerous subunit vaccines against SARS-CoV have been developed since the outbreak of SARS, the majority of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T120","span":{"begin":123,"end":130},"obj":"Chemical"}],"attributes":[{"id":"A120","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Numerous subunit vaccines against SARS-CoV have been developed since the outbreak of SARS, the majority of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T156","span":{"begin":0,"end":215},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Numerous subunit vaccines against SARS-CoV have been developed since the outbreak of SARS, the majority of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1)."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T506","span":{"begin":34,"end":42},"obj":"SP_10"},{"id":"T507","span":{"begin":85,"end":89},"obj":"SP_10"},{"id":"T508","span":{"begin":121,"end":130},"obj":"PG_1"},{"id":"T509","span":{"begin":142,"end":151},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T33727","span":{"begin":34,"end":42},"obj":"SP_10"},{"id":"T35137","span":{"begin":85,"end":89},"obj":"SP_10"},{"id":"T98807","span":{"begin":121,"end":130},"obj":"PG_1"},{"id":"T16034","span":{"begin":142,"end":151},"obj":"CHEBI:59132;CHEBI:59132"}],"text":"Numerous subunit vaccines against SARS-CoV have been developed since the outbreak of SARS, the majority of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1)."}